These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8652238)

  • 41. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
    J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
    Burdette-Radoux S; Wood ME; Olin JJ; Laughlin RS; Crocker AM; Ashikaga T; Muss HB
    Breast J; 2007; 13(3):274-80. PubMed ID: 17461902
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [High incidence-rate of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy (FEC100)].
    Fukazawa M; Kawaguchi H; Shigematsu H; Koga C; Mori E; Nishimura S; Nakamura Y; Satou S; Sawamura K; Kashiwaba K; Ohno S
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):395-8. PubMed ID: 22421766
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
    Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
    J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparisons of Cardiotoxicity and Efficacy of Anthracycline-Based Therapies in Breast Cancer: A Network Meta-Analysis of Randomized Clinical Trials.
    Mao Z; Shen K; Zhu L; Xu M; Yu F; Xue D; Li H; Xue C
    Oncol Res Treat; 2019; 42(7-8):405-413. PubMed ID: 31104059
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Epirubicin--results in breast cancer].
    Hartlapp JH
    Onkologie; 1986 Aug; 9 Suppl 1():3-7. PubMed ID: 3528968
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment.
    French Epirubicin Study Group
    J Clin Oncol; 2000 Sep; 18(17):3115-24. PubMed ID: 10963640
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer.
    Zhang XH; Hao S; Gao B; Tian WG; Jiang Y; Zhang S; Guo LJ; Luo DL
    Oncotarget; 2016 Dec; 7(51):84533-84543. PubMed ID: 27811367
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.
    Gianni L; Baselga J; Eiermann W; Guillem Porta V; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Llombart Cussac A; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez Lopez JJ; Mansutti M; Valagussa P; Bonadonna G;
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8715-21. PubMed ID: 16361558
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer.
    Levine MN; Bramwell V; Pritchard K; Perrault D; Findlay B; Abu-Zahra H; Warr D; Arnold A; Skillings J
    Eur J Cancer; 1992; 29A(1):37-43. PubMed ID: 1445744
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Analysis of the Risk Factors of Febrile Neutropenia Among 72 Women Receiving FEC in Early Breast Cancer Chemotherapy].
    Ishii N; Fujimori T; Kasagawa T; Udagawa I
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1555-1557. PubMed ID: 28133055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.
    Robidoux A; Buzdar AU; Quinaux E; Jacobs S; Rastogi P; Fourchotte V; Younan RJ; Pajon ER; Shalaby IA; Desai AM; Fehrenbacher L; Geyer CE; Mamounas EP; Wolmark N
    Clin Breast Cancer; 2010 Feb; 10(1):81-6. PubMed ID: 20133263
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
    French Adjuvant Study Group
    J Clin Oncol; 2001 Feb; 19(3):602-11. PubMed ID: 11157009
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
    Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
    J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D.
    Lee EK; Wong WW; Trudeau ME; Chan KK
    Breast Cancer Res Treat; 2015 Feb; 150(1):169-80. PubMed ID: 25694355
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial.
    Tan QW; Luo T; Zheng H; Tian TL; He P; Chen J; Zeng HL; Lv Q
    Chin J Cancer; 2017 Mar; 36(1):27. PubMed ID: 28270181
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of actual hospital costs versus DRG revenues for in-patient treatment of febrile neutropenia during adjuvant anthracycline plus/minus taxane-based chemotherapy for primary breast cancer.
    Jacobs VR; Mayer SC; Paessens BJ; Bernard R; Harbeck N; Kiechle M; Ihbe-Heffinger A
    Onkologie; 2011; 34(11):614-8. PubMed ID: 22104158
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel.
    Gu X; Jia S; Wei W; Zhang WH
    Tumour Biol; 2015 Jul; 36(7):5529-35. PubMed ID: 25682286
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
    Catimel G; Spielmann M; Dieras V; Kayitalire L; Pouillart P; Guastalla JP; Soler-Michel P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B; Chazard M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group.
    Fumoleau P; Devaux Y; Vo Van ML; Kerbrat P; Fargeot P; Schraub S; Mihura J; Namer M; Mercier M
    Drugs; 1993; 45 Suppl 2():38-45. PubMed ID: 7693420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.